Merck, The World’s Leading Research-Intensive Biopharmaceutical Company
- 20, Sep 2021 11:53
Merck is the world's leading research-intensive biopharmaceutical company. For 130 years, Merck (known as MSD outside the US and Canada) has been creating life, delivering drugs and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and enhance lives.
Merck is committed to increasing access to health nursing through policies, programs, and partnerships that reach far to the patients. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals - including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.
Merck is also committed to governance policies and practices that serve the interests of the company and its many stakeholders. For that reason, Merck devotes considerable time and resources to ensure that:
- Merck's policies reflect its values and business goals.
- Merck has an effective corporate governance structure.
- Merck operates in an open, honest, and transparent manner.
Merck's discoveries are guided by science and inspired by its patients. Merck's goal is to save and improve lives for generations. Merck has created many products and has US patents for its products. In accordance with Section 287 (a) Title 35 of the United States Code, the following products form part of Merck's rights to U.S. patents directed to the relevant product, such as:
- Animal health
U.S. Patent No. 8,475,818
BOVILIS Nasalgen 3 PMH
Live cattle vaccine
U.S. Patent No. 9,642,905
U.S. Patent No. 9,662,382
U.S. Patent No. 7,662,972
U.S. Patent No. 8,796,464
U.S. Patent No. 8,022,089
U.S. Patent No. 8,492,311
U.S. Patent No. 9,173,870
U.S. Patent No. 9,532,978
- Prescription pharmaceuticals
U.S. Patent No. 7,951,797
U.S. Patent No 10,098,892
(sugammadex sodium injection). For intravenous use U.S. Patent No. RE44,733
(doravirine / lamivudine / tenofovir disoproxil fumarate) Tablets
U.S. Patent No. 8,486,975
U.S. Patent No. 10,603,282
U.S. Patent No. 10,842,751
EBOLA ZAIRE VACCINE, LIVE U.S. Patent No. 8,012,489B2
HUMAN PAPILLOMAVIRUS QUADRIVALENT (TYPES 6, 11, 16, 18) VACCINE, RECOMBINANT U.S. Patent No. 7,476,389
HUMAN PAPILLOMAVIRUS 9-VALENT VACCINE, RECOMBINANT U.S. Patent No. 7,476,389
The products information above is just a few that Merck has created. If you want to find out more please visit www.merck.com or distributor, PT. Hartech Indonesia on its website hartechindonesia.com.